Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys

Author:

Carlisle Victoria RiceORCID,Maynard Olivia M.,Bagnall Darren,Hickman Matthew,Shorrock Jon,Thomas Kyla,Kesten Joanna

Abstract

(1) The harm-reduction benefits of opioid agonist treatment (OAT) are well-established; however, the UK government’s emphasis on “recovery” may be contributing to a high proportion of people leaving treatment and low retention rates. We wanted to develop a rich and nuanced understanding of the factors that might influence the treatment journeys of people who use OAT. (2) We explored factors at each level of the socioecological system and considered the ways these interact to influence treatment journeys in OAT. We carried out semi-structured interviews with people who use OAT (n = 12) and service providers (n = 13) and analysed data using reflexive thematic analysis. (3) We developed three themes representing participant perceptions of treatment journeys in OAT. These were: (1) The System is Broken; (2) Power Struggles; and (3) Filling the Void. (4) Conclusions: The data suggest that prioritisation of treatment retention is important to preserve the harm-reduction benefits of OAT. Stigma is a systemic issue which presents multiple barriers to people who use OAT living fulfilling lives. There is an urgent need to develop targeted interventions to address stigma towards people who use OAT.

Funder

Elizabeth Blackwell Institute, University of Bristol

Wellcome Trust

National Institute for Health and Social Care Research, School for Public Health Research

National Institute for Health and Care Research Applied Research Collaboration West

NIHR Health Protection Research Unit in Behavioural Science and Evaluation

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference94 articles.

1. World Health Organisation (2002). WHO Policy Perspectives on Medicines-The Selection of Essential Medicines.

2. UK Department of Health (2022, November 01). Drug Misuse and Dependence: UK Guidelines on Clinical Management, Available online: www.gov.uk/dh.

3. National Treatment Agency (2007). National Treatment Agency National Treatment Agency Independent Expert Working Group, Clinical Guidelines on Drug Misuse and Dependence Update: Consultation Draft June 2007.

4. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence;Mattick;Cochrane Database Syst. Rev,2009

5. Public Health England (2022, November 01). Part 1: Introducing Opioid Substitution Treatment (OST). London, Available online: https://www.gov.uk/government/publications/opioid-substitution-treatment-guide-for-keyworkers/part-1-introducing-opioid-substitution-treatment-ost.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3